Abstract |
Fifty-one human immunodeficiency virus-positive men with hypogonadism and wasting were randomized to receive testosterone enanthate, 300 mg i.m. every 3 weeks, or placebo for 6 months, followed by open-label testosterone administration for 6 months. Subjects initially randomized to placebo gained lean body mass (LBM) only after crossover to testosterone administration (mean change +/- standard error of the mean, -0.6 +/- 0.7 kg [months 0-6] vs. 1.9 +/- 0.7 kg [months 6-12]; P = .03). In contrast, subjects initially randomized to testosterone continued to gain LBM during open-label administration (2.0 +/- 0.7 kg [months 0-6] vs. 1.6 +/- 0.6 kg [months 6-12]; P = .62) and had gained more LBM at 1 year than did subjects receiving testosterone for only the final 6 months of the study (3.7 +/- 0.8 kg vs. 1.0 +/- 1.0 kg; P = .05). Testosterone administration results in sustained increases in LBM during 1 year of therapy in hypogonadal men with AIDS wasting.
|
Authors | S Grinspoon, C Corcoran, E Anderson, J Hubbard, T Stanley, N Basgoz, A Klibanski |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 28
Issue 3
Pg. 634-6
(Mar 1999)
ISSN: 1058-4838 [Print] United States |
PMID | 10194091
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Testosterone
- testosterone enanthate
|
Topics |
- Cross-Over Studies
- HIV Wasting Syndrome
(complications, drug therapy, physiopathology)
- Humans
- Hypogonadism
(complications, drug therapy)
- Male
- Quality of Life
- Testosterone
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Time Factors
- Weight Gain
|